CD31 as a Therapeutic Target in Atherosclerosis

Area of Science:

• Cardiovascular Biology
• Immunology
• Molecular Medicine

Background:

• CD31's role in atherosclerosis has been controversial since the 1990s, stalling therapeutic development.
• Early therapeutic approaches targeting CD31's adhesive properties were misinterpreted; its immunomodulatory function is key.
• Discovery of CD31's immunoreceptor tyrosine inhibitory motifs revealed its signaling capabilities.

Purpose of the Study:

• To investigate the therapeutic potential of CD31 agonists in atherothrombosis.
• To clarify the immunomodulatory role of CD31 in vascular inflammation and healing.

Main Methods:

• Analysis of CD31 expression on leukocytes in human atherothrombotic lesions and acute coronary syndromes.
• Administration of synthetic CD31 agonist peptides to atherosclerotic mice.
• Immobilization of CD31 agonist peptides onto coronary stents in pigs.

Main Results:

• Altered CD31 expression observed on leukocytes in unhealed atherothrombotic lesions.
• Loss of physiological CD31 immunomodulatory functions in blood leukocytes of acute coronary syndrome patients.
• Systemic CD31 agonist peptides promoted arterial healing in atherosclerotic mice.
• Immobilized CD31 agonist peptides improved stent integration in porcine coronary arteries.

Conclusions:

• CD31 agonists represent a promising therapeutic strategy for atherothrombosis.
• Targeting CD31's immunomodulatory function can enhance arterial healing and improve stent performance.